Neepa Shah1, Maureen G Maguire2, Daniel F Martin3, James Shaffer2, Gui-Shuang Ying2, Juan E Grunwald2, Cynthia A Toth4, Glenn J Jaffe4, Ebenezer Daniel2. 1. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: neepa.shah@uphs.upenn.edu. 2. Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. 4. Department of Ophthalmology, Duke University, Durham, North Carolina.
Abstract
PURPOSE: To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated withranibizumab or bevacizumabfor neovascular age-related macular degeneration (nAMD). DESIGN: Prospective cohort study within a randomized clinical trial. PARTICIPANTS: A total of 1185 CATT study subjects. METHODS:Baseline fluorescein angiography (FA) images of all CATT study eyes were evaluated for CME. Grading of other characteristics on optical coherence tomography (OCT) and photographic images at baseline and during 2-year follow-up was completed by readers at the CATT Reading Centers. Three groups were created on the basis of baseline CME and intraretinal fluid (IRF) status: (1) CME, (2) IRF without CME, (3) neither CME nor IRF. MAIN OUTCOME MEASURES: Visual acuity (VA) and total central retinal thickness (CRT) on OCT at baseline, year 1, and year 2. RESULTS: Among 1131 participants with images of sufficient quality for determining CME and IRF at baseline, 92 (8.1%) had CME, 766 (67.7%) had IRF without CME, and 273 (24.1%) had neither. At baseline, eyes with CME had worse mean VA (letters) than eyes with IRF without CME and eyes with neither CME nor IRF (52 vs. 60 vs. 66 letters, P < 0.001); higher mean total CRT (μm) on OCT (514 vs. 472 vs. 404, P < 0.001); and greater hemorrhage, retinal angiomatous proliferation (RAP) lesions, and classic choroidal neovascularization (CNV). All groups showed improvement in VA at follow-up; however, the CME group started and ended with the worst VA among the 3 groups. Central retinal thickness, although higher at baseline for the CME group, was similar at 1 and 2 years follow-up for all groups. More eyes with CME (65.3%) developed scarring during 2 years of follow-up compared with eyes with IRF without CME (43.8%) and eyes with neither CME nor IRF (32.5%; P < 0.001). CONCLUSIONS: In CATT, eyes with CME had worse baseline and follow-up VA, although all groups showed similar rates of improvement in VA during 2 years of follow-up. Cystoid macular edema seems to be a marker for poorer visual outcomes in nAMD because of underlying baseline retinal dysfunction and subsequent scarring.
RCT Entities:
PURPOSE: To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD). DESIGN: Prospective cohort study within a randomized clinical trial. PARTICIPANTS: A total of 1185 CATT study subjects. METHODS: Baseline fluorescein angiography (FA) images of all CATT study eyes were evaluated for CME. Grading of other characteristics on optical coherence tomography (OCT) and photographic images at baseline and during 2-year follow-up was completed by readers at the CATT Reading Centers. Three groups were created on the basis of baseline CME and intraretinal fluid (IRF) status: (1) CME, (2) IRF without CME, (3) neither CME nor IRF. MAIN OUTCOME MEASURES: Visual acuity (VA) and total central retinal thickness (CRT) on OCT at baseline, year 1, and year 2. RESULTS: Among 1131 participants with images of sufficient quality for determining CME and IRF at baseline, 92 (8.1%) had CME, 766 (67.7%) had IRF without CME, and 273 (24.1%) had neither. At baseline, eyes with CME had worse mean VA (letters) than eyes with IRF without CME and eyes with neither CME nor IRF (52 vs. 60 vs. 66 letters, P < 0.001); higher mean total CRT (μm) on OCT (514 vs. 472 vs. 404, P < 0.001); and greater hemorrhage, retinal angiomatous proliferation (RAP) lesions, and classic choroidal neovascularization (CNV). All groups showed improvement in VA at follow-up; however, the CME group started and ended with the worst VA among the 3 groups. Central retinal thickness, although higher at baseline for the CME group, was similar at 1 and 2 years follow-up for all groups. More eyes with CME (65.3%) developed scarring during 2 years of follow-up compared with eyes with IRF without CME (43.8%) and eyes with neither CME nor IRF (32.5%; P < 0.001). CONCLUSIONS: In CATT, eyes with CME had worse baseline and follow-up VA, although all groups showed similar rates of improvement in VA during 2 years of follow-up. Cystoid macular edema seems to be a marker for poorer visual outcomes in nAMD because of underlying baseline retinal dysfunction and subsequent scarring.
Authors: Francis Char DeCroos; Cynthia A Toth; Sandra S Stinnett; Cynthia S Heydary; Russell Burns; Glenn J Jaffe Journal: Ophthalmology Date: 2012-08-28 Impact factor: 12.079
Authors: Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris Journal: Ophthalmology Date: 2012-05-01 Impact factor: 12.079
Authors: Juan E Grunwald; Ebenezer Daniel; Gui-Shuang Ying; Maxwell Pistilli; Maureen G Maguire; Judith Alexander; Revell Whittock-Martin; Candace R Parker; Krista Sepielli; Barbara A Blodi; Daniel F Martin Journal: Ophthalmology Date: 2012-04-17 Impact factor: 12.079
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: Gui-shuang Ying; Jiayan Huang; Maureen G Maguire; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Ebenezer Daniel; Michael Klein; Dante Pieramici; John Wells; Daniel F Martin Journal: Ophthalmology Date: 2012-10-06 Impact factor: 12.079
Authors: Glenn J Jaffe; Daniel F Martin; Cynthia A Toth; Ebenezer Daniel; Maureen G Maguire; Gui-Shuang Ying; Juan E Grunwald; Jiayan Huang Journal: Ophthalmology Date: 2013-05-01 Impact factor: 12.079
Authors: Markus Ritter; Christian Simader; Matthias Bolz; Gábor G Deák; Ulrike Mayr-Sponer; Ramzi Sayegh; Michael Kundi; Ursula M Schmidt-Erfurth Journal: Br J Ophthalmol Date: 2014-07-30 Impact factor: 4.638
Authors: Ebenezer Daniel; Juan E Grunwald; Benjamin J Kim; Maureen G Maguire; Glenn J Jaffe; Cynthia A Toth; Frederick L Ferris; Daniel F Martin; James Shaffer; Gui-Shuang Ying Journal: Ophthalmol Retina Date: 2017 Jan-Feb
Authors: Ebenezer Daniel; Gui-Shuang Ying; Benjamin J Kim; Cynthia A Toth; Frederick Ferris; Daniel F Martin; Juan E Grunwald; Glenn J Jaffe; Joshua L Dunaief; Wei Pan; Maureen G Maguire Journal: Ophthalmology Date: 2018-11-23 Impact factor: 12.079
Authors: Laurent Kodjikian; Mariacristina Parravano; Andreas Clemens; Rosa Dolz-Marco; Frank G Holz; Marion R Munk; Massimo Nicolò; Federico Ricci; Rufino Silva; S James Talks; Rohini Kumar Verma; Javier Zarranz-Ventura; Sandrine A Zweifel Journal: Eye (Lond) Date: 2021-04-01 Impact factor: 3.775
Authors: Sharon D Solomon; Kristina Lindsley; Satyanarayana S Vedula; Magdalena G Krzystolik; Barbara S Hawkins Journal: Cochrane Database Syst Rev Date: 2019-03-04